Matinas BioPharma Stock Jumps After Meningitis Candidate Data
Matinas BioPharma Holdings Inc (NYSE:MTNB) has announced positive data from the first two cohorts of the Phase 2 EnACT trial of…
Matinas BioPharma Announces Data In Ongoing EnACT TrialOof MAT2203 For Treatment Of Cryptococcal Meningitis; Mean Early Fungicidal Activity Exceeded Prespecified Primary Endpoint Threshold
– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20
Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
Matinas BioPharma Hldgs Q2 EPS $(0.02) Beats $(0.03) Estimate
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.03) per share
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
Matinas BioPharma Hldgs Earnings Preview
Matinas BioPharma Hldgs (AMEX:MTNB) announces its next round of earnings this Tuesday, August 10. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Matinas BioPharma Hldgs: Return On Capital Employed Insights
Matinas BioPharma Hldgs (AMEX:MTNB) reported Q1 sales of $33.33 thousand. Earnings fell to a loss of $6.35 million, resulting in a 2.09% decrease from last quarter. Matinas BioPharma Hldgs collected $62.50 thousand in revenue during Q4, but reported earnings showed a $6.49 million loss.
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell
• Revlon (NYSE:REV) is likely to report earnings for its first quarter.
• Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.